Athersys, Inc. (Nasdaq: ATHX) will release its year-end 2020 financial results on March 25, 2021, at 4:00 PM ET, followed by a conference call at 4:30 PM ET. The previously scheduled Investor Day for February 16 has been canceled, and updates will be provided during the earnings call. Shareholders are encouraged to join via the webcast or phone registration. A replay will be available on the company's website after the call.
Athersys, Inc. (NASDAQ: ATHX) has entered a cooperation agreement with its largest shareholder, HEALIOS K.K., aimed at advancing the commercialization of its MultiStem therapy in Japan. The agreement includes a commitment to expedite negotiations on key matters vital for success in the Japanese market. Additionally, Dr. Hardy TS Kagimoto has agreed to dismiss litigation pertaining to shareholder rights. Athersys anticipates significant progress with ongoing trials for stroke and ARDS, expecting results later this year. This collaboration aims to enhance the potential impact of MultiStem therapy for patients in need.
Athersys, Inc. (Nasdaq: ATHX) announced the immediate resignation of Dr. Gil Van Bokkelen as Chairman and CEO. William (B.J.) Lehmann, the current President and COO, has been appointed as Interim CEO. The Board is initiating a search for a permanent CEO to guide the company through its commercial phase. Dr. Ismail Kola has become Chairman of the Board. Athersys is advancing its late-stage clinical programs, including trials in Japan, and is preparing for key data readouts and a go-to-market strategy for its MultiStem product. The scheduled Virtual Investor Day has been postponed.
Athersys, Inc. (NASDAQ: ATHX) has commenced a Phase II clinical study named MATRICS-1 to evaluate its MultiStem® cell therapy for treating traumatic injuries. Conducted at Memorial Hermann-Texas Medical Center, the study aims to enroll 156 patients experiencing severe hemorrhage. Funded by a grant from the Medical Technology Enterprise Consortium and the Memorial Hermann Foundation, the trial will assess the safety and efficacy of MultiStem in preventing complications post-injury. This initiative targets a significant unmet medical need, as trauma remains a leading cause of mortality in individuals under 45.
Athersys, Inc. (NASDAQ: ATHX) announces the appointment of three new board members: Ms. Katherine Kalin, Ms. Jane Wasman, and Mr. Baiju R. Shah, enhancing its leadership team with extensive healthcare and biopharma experience. These strategic leaders aim to guide the company as it prepares for potential commercialization of its investigational cell therapy, MultiStem®. Dr. Lee Babiss, a director since 2010, has retired from the board, and the company expressed gratitude for his contributions over the past decade.
Athersys, Inc. (NASDAQ: ATHX) reported a net loss of $22.5 million for Q3 2020, compared to a $12 million loss in Q3 2019. Revenue increased to $0.1 million, up from negative $0.4 million the prior year, largely due to collaboration with Healios. Research and development expenses surged to $18.5 million, primarily driven by clinical trial costs. The company has received RMAT designation from the FDA for its MultiStem® treatment for acute respiratory distress syndrome and is advancing clinical trials for COVID-19 and ischemic stroke. Athersys ended the quarter with $61.7 million in cash.
Athersys, Inc. (Nasdaq: ATHX) is set to announce its third quarter 2020 financial results on November 9, 2020, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM. Shareholders can participate in the call via a webcast or phone registration. A replay will be available shortly after the event on the company’s website until November 16, 2020. Athersys focuses on developing therapeutic product candidates, particularly the MultiStem® cell therapy, targeting various diseases. The call aims to provide insights into financial performance and ongoing clinical trials.